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Objective: Tumor metastasis and resistance to chemotherapy are two critical factors that
contribute to the high death rate of colorectal cancer (CRC) patients. Metastasis is
facilitated by the epithelial-mesenchymal transition (EMT) of tumor cells, which has
emerged not only as a fundamental process during metastasis, but is also a key
process leading to chemoresistance of cancer cells. However, the underlying
mechanisms of EMT in CRC cell remain unknown. Here, we aim to assess the role of
dual serine/threonine and tyrosine protein kinase (DSTYK) in CRC metastasis and
chemoresistance.
Methods: To study the role of DSTYK in TGF-b-induced EMT, we employed techniques
including Crispr/Cas9 knockout (KO) to generate DSTYK KO cell lines, RT-PCR to detect
the mRNA expression, immunoﬂuorescence analyses, and western blots to detect protein
levels of DSTYK in the following 4 cell lines: control LS411N-TbRII and LS411N-TbRII/
DSTYK KO, control LS513 and LS513/DSTYK KO cells, treated with/without TGF-b. The
effects of DSTYK on apoptosis were investigated by MTT assays, ﬂow cytometry assays,
and TUNEL assays. The expression of DSTYK in CRC patients and its correlation with
EMT markers were determined by bioinformatics analysis. For in vivo analysis, both
xenograft and orthotopic tumor mouse models were employed to investigate the function
of DSTYK in chemoresistance and metastasis of tumors.
Results: In this study, we demonstrate that the novel kinase DSTYK promotes both TGFb-induced EMT and the subsequent chemoresistance in CRC cells. DSTYK KO
signiﬁcantly attenuates TGF-b–induced EMT and chemoresistance in CRC cells.
According to the Gene Expression Omnibus (GEO) database, the expression of DSTYK
is not only positively correlated to the expression of TGF-b, but proportional to the death
rate of CRC patients as well. Evidently, the expression of DSTYK in the metastatic
colorectal cancer samples from patients was signiﬁcantly higher than that of primary
colorectal cancer samples. Further, we demonstrate in mouse models that
chemotherapeutic drug treatment suppresses the growth of DSTYK KO tumors more
effectively than control tumors.
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Conclusion: Our ﬁndings identify DSTYK as a novel protein kinase in regulating TGF-b–
mediated EMT and chemoresistance in CRC cells, which deﬁnes DSTYK as a potential
therapeutic target for CRC therapy.
Keywords: dual serine/threonine and tyrosine protein kinase, colorectal cancer, epithelial-mesenchymal transition,
transforming growth factor-b, chemoresistance, metastasis

reported that mutations of DSTYK are associated with hereditary
spastic paraplegia type 23 (Lee et al., 2017). Also, DSTYK has
been shown to play a predominant role in suppressing caspasedependent apoptosis caused by ultraviolet (UV) light exposure in
skin cells (Lee et al., 2017). However, the role of DSTYK in CRC
metastasis and chemoresistance remains unknown. To address
this question, we characterized the function of DSTYK not only
in a cellular model, but also in a xenograft mouse model. We
further evaluated the role of DSTYK in CRC chemoresistance
and metastasis with an orthotopic mouse model.
In this study, we sought to investigate the biological function
of DSTYK in CRC. We found that DSTYK facilitates TGF-binduced EMT and promotes chemoresistance in two CRC cell
lines, LS411N-TbRII and LS513, by inhibiting apoptosis.
Additionally, we evaluated DSTYK as a novel therapeutic
target for CRC therapy in mouse models. The reported
ﬁndings will increase our understanding of the function of
DSTYK in CRC and will enhance our ability in developing
treatments to prevent both EMT and chemoresistance. Thus,
our ﬁndings present DSTYK as a highly promising therapeutic
target to signiﬁcantly improve CRC treatment.

INTRODUCTION
Colorectal cancer (CRC) is the third leading cause of cancer
death worldwide; the 5-year relative survival rate is only 53% to
65% in spite of many efforts to improve diagnosis and
chemotherapy (Torre et al., 2015). Currently, tumor metastasis
and resistance to chemotherapeutic treatment are considered as
two critical factors that contribute to the death of CRC patients
(Tsoumas et al., 2018). Approximately 25% of newly diagnosed
CRC patients develop metastases and 50% of all CRC patients die
from metastatic disease (Obrand and Gordon, 1997). The
process of epithelial–mesenchymal transition (EMT) has been
shown to play a critical role in promoting metastasis in
epithelium-derived carcinoma (Thomson et al., 2005).
Metastasis is initiated through the EMT of tumor cells, in
which cells undergo a switch from a polarized, epithelial
phenotype to a highly motile and invasive ﬁbroblastic or
mesenchymal phenotype (Singh and Settleman, 2010). EMT
has emerged not only as a fundamental process during normal
embryonic development (Lim and Thiery, 2012) and in adult
tissue homeostasis (Antonello et al., 2015), but it also is
aberrantly activated during the metastatic progression in
cancer (Tsai and Yang, 2013; Aiello et al., 2017; Lu and Kang,
2019). In addition to metastasis, EMT is strongly associated with
chemoresistance upon chemotherapeutic treatment. Tumor cells
with the capacity of chemoresistance usually show a strong
mesenchymal phenotype (Shah et al., 2007) and vice versa,
tumor cells undergoing EMT also acquire the capability of
chemoresistance (Yin et al., 2007). A number of cytokines and
their signaling pathways have been shown to regulate EMT, such
as transforming growth factor-b (TGF-b), Wnts, Notch,
ﬁbroblast growth factors (FGFs) and bone morphogenetic
protein (BMP), etc. Preventing EMT will increase signiﬁcantly
the drug sensitivity of tumor cells and the survival rate of human
CRC patients (Ren et al., 2013; Fischer et al., 2015; Zheng et al.,
2015). TGF-b is an established inducer of EMT; however, it
remains unclear how this signaling pathway induces EMT and
whether there are other novel signaling pathways or elements
involved in EMT (Xu et al., 2009). Therefore, the potential for
improving chemotherapeutic efﬁcacy in CRC patients critically
depends on improving our understanding of the mechanism by
which TGF-b induces EMT in CRC cells leading to
chemoresistance and metastasis (Goldberg et al., 2004;
Goldberg et al., 2006).
DSTYK is a dual serine/threonine and tyrosine protein kinase
expressed in multiple human tissues including brain, heart,
kidney, lung, colon, and muscle (Peng et al., 2006). The
functions of DSTYK are barely known, although it has been
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MATERIALS AND METHODS
Cell Culture and Reagents
Human colorectal cancer cell lines LS411N and LS513 were
purchased from the American Type Culture Collection (ATCC,
Manassas, VA, United States), and the LS411N-TbRII cell line
was generated in our lab by overexpressing TGF-b receptor II
(TbRII) in LS411N cells. All cells were cultured in RPMI-1640
medium containing 10% FBS and 1% antibiotic and antimycotic
cocktail (Millipore). The cells were maintained at 37°C with 5%
CO2. The culture medium was refreshed two or three times a
week. TGF-b signaling pathway inhibitor LY2109761 was
purchased from MedChemExpress LLC.

Annexin V-FITC/PI Double-Staining Assay
Cells were seeded in 12-well plates and incubated overnight for
attachment, then the media was replaced with new media for either
TGF-b or oxaliplatin (OXA) treatment. After treatment, all ﬂoating
and adherent cells were collected by trypsinization. All cells were
collected by centrifugation and washed three times in phosphatebuffered saline (PBS) before staining with Annexin V-FITC and PI
according to the speciﬁed protocol (Cell Signaling Technology, cat#
6592). Brieﬂy, cells were resuspended in 500 µl 1× binding buffer
containing 5 µl Annexin V-ﬂuorescein isothiocyanate (FITC) and
10 µl propidium iodide (PI) in the dark for 5 min. The stained cells
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were analyzed with a ﬂow cytometer and the data were analyzed
using FlowJo cell software (FlowJo, LLC, Ashland, Ore) to measure
apoptotic cells, live cells, and necrotic cells. Early apoptosis was
designated as annexin V positive/PI negative and late apoptosis was
designated as annexin V positive/PI positive; necrosis was deﬁned
as annexin V negative/PI positive.

cells were cultured on coverslips in 24-well plates and ﬁxed in 4%
paraformaldehyde in PBS. The TdT reaction was performed for 1 h
at 37 °C in a humidiﬁed chamber. Then, the cells were stained with
4, 6-diamidino-2-phenylindole (DAPI) for 5 min. Fluorescence
signal was examined, and photos were taken with a Leica
ﬂuorescence microscopy.

MTT Assay and Clonogenic Assay

Immunoﬂuorescence Staining

The MTT assay was performed as previously described (Jiang
et al., 2016). Brieﬂy, 5,000 cells per well of LS411N-TbRII or
LS513 cells were seeded in a 96-well dish with 200 ml RPMI
containing 10% FBS and incubated in a 37 °C and 5% CO2
incubator. Post-plating (24 h), various concentrations of OXA or
vehicle were added. Following a 48 h treatment, cell viability was
assessed by the MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5diphenyl tetrazolium bromide; Sigma) assay according to the
manufacturer’s protocol. The viable fraction is expressed as the
percentage of vehicle-treated control cells. For the clonogenic
assay, the same number of cells were seeded into each well in 6well plates. After drug treatment for 2 days, the media were
changed and the cells were continuously cultured for additional 7
to 10 days in a drug-free medium and followed by ﬁxation and
staining with crystal violet and photography.

For immunoﬂuorescence, cells cultured on coverslips were ﬁxed
in 4% paraformaldehyde for 10 min, permeabilized with 0.1%
Triton X-100 for 15 min and blocked with 3% BSA (all in PBS)
for 30 min. Cells then were incubated sequentially at 4°C
overnight with primary antibodies and then with Alexa Fluor
488-labeled secondary antibodies (Abcam). Nuclei were
counterstained with DAPI (Vector Laboratories, 1:500).
Confocal ﬂuorescence images were taken with a Leica TCS
SP8 confocal microscope.

DSTYK Knockout (KO) via Crispr/Cas9
Cells were transfected with DSTYK Crispr/Cas9 KO Plasmid
(Santa Cruz, sc-404521) and HDR plasmids (Santa Cruz, sc404521-HDR) using lipofectamine 3000 (ThermoFisher
Scientiﬁc) according to the manufacturer’s instructions. After
transfection for 48 h, the cells were cultured in puromycincontaining media for selection and cloning of DSTYK knockout
(KO) cells. DSTYK KO was conﬁrmed by WB analysis.

Western Blotting
Western blot (WB) analyses were performed as previously
described (Jiang et al., 2016). Total proteins were separated by
loading a speciﬁed amount of whole cell lysate on a denaturing 8%
to 15% SDS-polyacrylamide gel followed by transferring to
polyvinylidene diﬂuoride (PVDF) membranes. Membranes were
blocked with a 5% non-fat milk solution and incubated with
primary antibodies for vimentin, Bax, Bcl-2, Bim (Cell Signaling
Biotechnology), E-cadherin (BD Biosciences), N-cadherin (BD
Biosciences), DSTYK (Thermo Fisher Scientiﬁc) or Hsp90
(Santa Cruz Biotechnology). Secondary antibodies (Thermo
Fisher Scientiﬁc) conjugated to horseradish peroxidase and ECL
(Bio-rad) were used to detect signals that were visualized by
chemiluminescence. At least three independent experiments
were performed for each western blotting assay.

Xenograft and Metastasis Experiments in
Mice
All animal experimental procedures are consistent with our mice
protocols that were approved by the Institutional Animal Care
and Use Committee at East Tennessee State University (ETSU).
NOD.CB17-Prkdcscid/J mice (SCID), 4–6 weeks old, were
purchased from the Jackson laboratory and were maintained at
our animal facility under the speciﬁed pathogen-free condition.
In all experiments, male mice were randomly selected. In the
xenograft mouse model, 2 × 105 LS411N-TbRII cells or 2 × 105
LS513 cells were injected into the ﬂanks of 7- to 8-week-old SCID
mice. When the tumor volume reached about 50 mm 3 ,
mice received therapy by intraperitoneal (i.p.) injection of the
chemotherapeutic agent oxaliplatin (OXA). OXA (10–20 mg/kg)
was administered to mice 2 times/week intraperitoneally for 3–4
weeks. Finally, mice were euthanized by carbon dioxide,
subjected to necropsy, and tissues collection. Tumors were
measured every 2 to 3 days using calipers and calculated using
a standard formula: width2 × length × 0.52. Body weights were
measured weekly.
In the orthotopic metastatic models, 5 × 104 cells (LS411NTbRII or LS513) were injected into the cecum wall of mice at the
age of 8 weeks. When signs of disease were visible, mice were
euthanized by carbon dioxide, subjected to necropsy, and
inspected for tumors in cecum, liver or lung. Primary
carcinomas in the cecum and metastases in the livers were
collected for histological analysis. Each study was repeated
three times unless otherwise speciﬁed.

Real Time-Quantitative PCR (RT-qPCR)
Total mRNA was extracted by using the Oligotex Direct mRNA
Mini Kit (Qiagen) and cDNA was synthesized from 1 mg of
mRNA by using High-Capacity cDNA Reverse Transcription Kits
(Bio-Rad) plus SYB® Gene Expression Assay Mix, sterile water,
and Fast Universal PCR Master Mix (Applied Biosystems) to
measure speciﬁc gene expression. Real-time PCR was carried out
using the CFX Real-Time PCR Detection system (Bio-Rad). The
expression of a target gene was calculated relative to the expression
of b-actin.

Terminal Deoxynucleotidyl TransferaseMediated dUTP Nick End-Labeling
(TUNEL) Assay
The TUNEL assay was performed as described in the supplier’s
protocol from ABP Biosciences (catalog number: A050). Brieﬂy,
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Tumor Tissues From Patients

Statistical Analysis

Specimens [patients (n=13), normal, pre-tumor, tumor,
metastasis] as shown in Supplemental Table S1 were obtained
from patients who had undergone CRC resection and with
tumor grade categorized as well differentiated, moderately
differentiated, poorly differentiated, or undifferentiated by three
pathologists. Informed consent was obtained from all patients
before surgery, and the use of histological sections was approved
by our ethics review committee.

All results are expressed as the mean ± SD or SEM. Mice and
sample groups were indicated. Data were analyzed using the
unpaired student t-test, and treatment differences were
considered signiﬁcant at P value < 0.05. Kaplan-Meier survival
curves were generated using GraphPad Prism software.

Immunohistochemistry

DSTYK Is Upregulated in Human CRC
Metastatic Progression

RESULTS

Parafﬁn-embedded tissue sections (5 µm thick) were stained with
anti-DSTYK antibody, anti-cleaved caspase 3 antibody (1:100, Cell
Signaling Biotechnology) or anti–Ki-67 antibody (1:100, Cell
Signaling Biotechnology) overnight at 4°C. The signals were
detected using the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA) following the manufacturer’s
protocol. Hematoxylin was used for counterstaining. The signal
intensity was scored using the following scale: 0 (negative), 1 (very
weak), 2 (weak), 3 (moderate), 4 (middle strong), 5 (strong), and 6
(very strong). The staining was considered to be positive if the sum
of distribution and intensity scores was greater than 2. Tissue
microarray (TMA) blocks were prepared for pre-metastatic and
metastatic colorectal cancer samples, primary colorectal cancer
samples, and paired normal colon counterparts, following our
above immunohistochemistry protocol.

A

From our previous gene microarray analysis, we found that the
expression of DSTYK is signiﬁcantly higher in TGF-b-induced
EMT in CRC cells. To further investigate the role of DSTYK in
the progression of human CRC, we analyzed the data of DSTYK
mRNA expression in The Gene Expression Omnibus (GEO)
database of the human CRC patients. DSTYK expression is
positively proportional to the expression of TGF-b, mesenchymal
markers vimentin (VIM) and N-cadherin (CDH2) (Figures 1A, B,
D) in tumor tissues from human CRC patients, whereas it is
inversely correlated to epithelial marker E-cadherin (CDH1)
expression (Figure 1C). These ﬁndings imply that DSTYK may
be involved in regulating EMT. We also found that higher levels of
DSTYK are correlated with poor prognosis of colorectal cancer
patients as indicated by the inversely proportional correlation

B

E

D

C

G

F

FIGURE 1 | DSTYK is associated with the metastasis of human colorectal cancer. (A) Scatter plot showing the correlation between the mRNA levels of DSTYK and
TGF-b, (B) DSTYK and vimentin (VIM), (C) DSTYK and E-cadherin (CDH1), and (D) DSTYK and N-cadherin (CDH2) in the human TCGA colon cancer database.
(E) Kaplan-Meier curve assessing the correlation between DSTYK expression and patients’ survival rate obtained from 652 patients in The Gene Expression
Omnibus (GEO) database. Blue line represents metastatic colorectal cancer patients with high DSTYK expression (n=154) and the red line represents patients with
low DSTYK expression (n=498) in the GSE 17538 dataset. SPSS repeated measures, general linear model. (F) Representative images of human colorectal primary
tumors and secondary tumors subjected to immunohistochemical (IHC) analysis with DSTYK antibody. Images were taken after IHC staining. Scale bar, 50 µm.
(G) Quantiﬁcation of the staining signals from IHC analyses of DSTYK in both primary and secondary tumor tissues. Data are presented as means ± SEM. for n= 20.
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effects of the TGF-b signaling pathway can be warranted in
experiments performed with this cell line. LS513 is another TGFb competent cells line being used as a parallel control. LS411NTbRII cells and LS513 cells were treated with TGF-b1 (1 ng/ml) for
5 days to induce EMT. During this 5-day treatment, both cells
showed a morphology change from the cobblestone-like epithelial
cells to the ﬁbroblast-like cells (Figure 2A). Whole cell lysates from
TGF-b-treated cells were subjected to immunoblotting analysis to
detect the expression of epithelial cell marker E-cadherin, and
mesenchymal markers, N-cadherin, and vimentin. The amount of
E-cadherin was signiﬁcantly decreased in cells treated with TGF-b,
which is indicated by both immunoﬂuorescence and
immunoblotting assays (Figures 2B, C), whereas the amounts of
N-cadherin and vimentin were signiﬁcantly increased in those cells
with TGF-b treatment when compared to control (Figure 2C).
These ﬁndings support the conclusion that EMT is induced by
TGF-b. Further, we determined whether the level of DSTYK mRNA
is modiﬁed upon TGF-b treatment. We performed both reverse
transcription PCR (Figure 2D) and real-time PCR with mRNA
extracts from the indicated time course with TGF-b treatment
(Figure 2F). The results from both PCR analyses indicate that

between the level of DSTYK and the survival rate of CRC patients
(Figure 1E). In addition, we performed immunohistochemical
(IHC) staining of 20 primary human colorectal tumors and 20
secondary tumors (metastases from primary colorectal tumors)
including those in lungs and livers (normal, pre-tumor, tumor,
metastasis as shown are from patients listed in Supplemental Table
1 (Figure 1F). The quantiﬁed results showed that the mean signal of
DSTYK in secondary tumors is signiﬁcantly higher than that in
primary tumors (Figure 1G), which implies that DSTYK plays an
important role in CRC metastasis. All these data suggest that
DSTYK may contribute to human CRC metastasis.

TGF-b Induces DSTYK Expression and
EMT in Colorectal Cancer Cells
To validate that DSTYK is involved in TGF-b-induced EMT in
CRC, we used two cell lines, LS411N-TbRII and LS513. Because
LS411N cells have a defective TGF-b receptor II (TbRII) and are not
responsive to TGF-b treatment (de Miranda et al., 2015), we
ectopically expressed wild-type (WT) TbRII in LS411N cells.
After WT TbRII was introduced, LS411N cells became TGF-b
competent and were deﬁned as LS411N-TbRII cells. The speciﬁc

A

B

C

D

F

E

FIGURE 2 | TGF-b induces EMT in LS411N-TbRII cells and LS513 cells. (A) Morphological change of cells before and after 5 days of TGF-b (1 ng/ml) treatment.
Scale bar: 100 µm. (B) Representative immunostaining of E-cadherin in LS411N-TbRII cells and LS513 cells before and after 5 days TGF-b (1 ng/ml) treatment.
Scale bar, 50 mm. (C) WB analyses to detect the protein levels of epithelial marker E-cadherin and mesenchymal markers, N-cadherin and vimentin. Hsp90 was
used as loading control. All experiments were repeated at least three times and similar results were observed. (D) RT-PCR analyses of DSTYK mRNA levels during
TGF-b-induced EMT. b-actin was used as control. (E) Immunoblotting analysis to detect the protein levels of DSTYK during TGF-b-mediated EMT. Hsp90 was used
as loading control. All experiments were repeated at least three times and similar results were observed. (F) Real-time PCR analyses to detect the upregulation of
DSTYK expression during TGF-b-mediated EMT. Data are shown as mean ± SD, n=3 independent experiments.
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found that there were no signiﬁcant differences of the protein levels
of epithelial marker E-cadherin and mesenchymal markers Ncadherin and vimentin before and after TGF-b treatment in
DSTYK/KO cells (Figure 3A). Interestingly, DSTYK/KO
signiﬁcantly decreased the TGF-b-mediated migration ability of
LS411N-TbRII cells and LS513 cells when compared to control
groups, as demonstrated by wound-healing assays (Figure 3B). Cell
invasion assays were performed using the Matrigel cell invasion
assay kit (Cell Biolab, Inc.) to compare the invasive capacity between
control and DSTYK/KO cells before and after a 5-day TGF-b
treatment. Our results demonstrated that the invasive capability of
DSTYK/KO cells is signiﬁcantly lower than that of control cells after
TGF-b treatment (Figures 3C, D, E). All the above data suggest that
DSTYK is essential for TGF-b-induced EMT and subsequent cell
invasion in both LS411N-TbRII cells and LS513 cells.

DSTYK message is upregulated during this EMT induction.
Furthermore, immunoblotting analyses showed that both
LS411N-TbRII cells and LS513 cells carry a low level of DSTYK
proteins and DSTYK protein levels were signiﬁcantly increased
during TGF-b-mediated EMT in both cell lines (Figure 2E). To
conﬁrm that an intact TGF-b signaling pathway is required for
DSTYK upregulation, we employed a commercially available TGFb signaling inhibitor, LY2109761, in both LS411N-TbRII cells and
LS513 cells. The results show that TGF-b has no effect on DSTYK
levels in the presence of the TGF-b signaling inhibitor
(Supplemental Figures 1A, B). Also, we did not ﬁnd any TGF-b
treatment-induced upregulation of DSTYK in LS411N cells in
which the endogenous mutated TbRII is not functional, and they
are not responsive to TGF-b treatment (Supplemental Figure 1C).
Overall, these results conﬁrmed that TGF-b induces EMT in
LS411N-TbRII cells and LS513 cells and that DSTYK is
upregulated by TGF-b.

TGF-b Induces Apoptosis Instead of EMT
in the Absence of DSTYK

DSTYK Is Required for TGF-b-Induced
EMT

As shown above, in DSTYK/KO cells the protein levels of epithelial
markers and mesenchymal markers displayed no signiﬁcant changes
before and after TGF-b treatment. We further characterized the
status of these cells after 5 days TGF-b treatment. DSTYK/KO cells
not only failed to display a mesenchymal phenotype, but also
appeared to enter into a non-proliferative, shrunk state after 5
days TGF-b treatment (Figure 4A), suggestive of autophagy,

To test whether DSTYK is indispensable for TGF-b-induced EMT,
we employed the Crispr/Cas9 technique to stably knock out DSTYK
expression in both LS411N-TbRII and LS513 cells. We treated these
two cells with TGF-b for a 5-day time course, and performed an
immunoblotting analysis to detect EMT markers (Figure 3). We

A

C

B

D

E

FIGURE 3 | DSTYK is required for TGF-b-induced EMT in CRC cells. (A) Immunoblotting analyses were employed to compare the protein levels of DSTYK and the
EMT markers E-cadherin, N-cadherin and vimentin between control cells and DSTYK/KO cells during a 5-day TGF-b treatment timecourse. Hsp90 was used as
loading control. (B) Representative images of a wound healing assay with LS411N-TbRII cells and LS513 cells. (C) Schematic of the principle of a cell invasion
assay. (D) Top: The cells on the basement membrane before invasion at 0h. Middle: The cells migrating to the bottom of membrane after 36h invasion. Bottom: The
cells on the bottom of membrane after 36h invasion from 5 days of TGF-b treatment. Representative images of the lower chamber of the trans-well invasion assay in
different treatment groups are shown for LS411N-TbRII or LS513 cells. (E) The quantiﬁcation of cell invasion assays in (D). All the experiments were repeated at least
three times. **P < 0.01. Data are shown as mean ± SD, n=3 independent experiments.
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necrosis, or apoptosis. We performed immunoblotting analysis to
detect the protein markers for autophagy (LC3B and p62) and for
necrosis (cyclophilin A and HMGB1) (15, 16). Immunoblotting
results clearly indicated that neither autophagy makers nor necrosis
makers demonstrated any signiﬁcant modulation by TGF-b
treatment (data not shown), which excludes the involvement of
both autophagy and necrosis. To determine whether apoptosis is
induced by TGF-b in DSTYK/KO cells, terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assays were performed
(Jiang et al., 2016). The results demonstrate that strong apoptotic
signals were induced in DSTYK/KO cells after 5 days TGF-b
treatment (Figure 4B). Moreover, ﬂow cytometry analysis was
performed to detect the cell surface apoptotic marker annexin V
and the loss of plasma membrane integrity (uptake of PI) (Jiang et al.,
2016). Our results show that after 5 days TGF-b treatment, there are
few annexin V-positive control cells, whereas the majority of
DSTYK/KO cells show strong annexin V signals indicative of
apoptosis (Figure 4C). Interestingly, after 5 days of TGF-b
treatment, the level of the anti-apoptotic protein Bcl-2 was not
affected, whereas the pro-apoptotic protein Bax was increased in
DSTYK/KO cells when compared to control cells. Bim protein level
also remained constant (Figures 4D, E). Therefore, our results
suggest that in the absence of DSTYK, TGF-b may induce
apoptosis instead of EMT in CRC cells, and DSTYK may inhibit
cell apoptosis through Bax during TGF-b-induced EMT.

et al., 2015; Li et al., 2019), we next performed experiments to
assess the role of DSTYK in drug resistance. To test whether
DSTYK also plays a role in the apoptosis induced by
chemotherapeutic drug treatment in LS411N-TbRII and LS513
cells, we treated both control cells and DSTYK/KO cells with
oxaliplatin (OXA) at different concentrations. We noticed that
DSTYK/KO cells displayed more chemosensitivity upon
chemotherapeutic drug treatment, which is indicated by more
apoptosis-mediated cell death in both MTT cell survival assays
(Figures 5A, B) and ﬂow cytometry analyses with apoptosis
marker annexin V (Figures 5C–F) and clonogenic assays
(Figures 5G, H). These data suggest that there is more
apoptosis in DSTYK/KO cells treated with OXA than in control
cells treated with OXA. In addition, we established the ectopic
DSTYK-overexpression (OE) LS411N-TbRII and LS513 cell lines
as shown in Supplemental Figures 2A, B. We treated both control
cells and DSTYK/OE cells with OXA at different concentrations.
We found that DSTYK/OE cells display more chemoresistance
upon chemotherapeutic drug treatment, which is indicated
by MTT cell survival assays (Supplemental Figures 2C, D)
and ﬂow cytometry analyses with apoptosis marker annexin V
(Supplemental Figures 2E, F). Therefore, our results further
conﬁrm that DSTYK promotes chemoresistance during
chemotherapeutic drug treatment in CRC cells.

DSTYK Promotes Chemoresistance in
CRC Cells

Inhibition of DSTYK Expression Enhances
Chemotherapy and Attenuates Metastasis
in Mouse Model

Since EMT has been extensively reported to contribute to
chemoresistance in chemotherapeutic drug treatment (Fischer

To provide in vivo evidence that DSTYK/KO can attenuate
chemoresistance and EMT, we employed both xenograft and

A

D

B

C

E

FIGURE 4 | TGF-b induces apoptosis in the absence of DSTYK. (A) Morphological differences between control cells and DSTYK/KO cells after 5 days TGF-b
treatment. (B) TUNEL assays to detect the apoptotic signals in control cells and DSTYK/KO cells after 5 days TGF-b treatment. The green color indicates DNA
fragmentation. Scale bar, 100 mm. (C) Flow cytometry analysis to compare the levels of cell death by staining with cell surface apoptotic marker annexin V and the
necrotic marker PI in control and DSTYK/KO cells after 5 days TGF-b treatment. Western blot analysis of apoptosis-related proteins including cleaved-caspase-3,
Bcl-2, Bim, and Bcl2-associated X (Bax) in control and DSTYK/KO LS411N-TbRII cells (D) and LS513 cells (E) after 5 days TGF-b treatment. b-actin is used as
loading control. All experiments were repeated for at least three times, and similar results were observed.
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A

B

C

D

E

F

G

H

FIGURE 5 | DSTYK inhibits chemotherapeutic agent-induced apoptosis. (A, B) MTT assays to compare the chemoresistance between control and DSTYK/KO cells
after 3 days OXA treatment. Data are presented as means ± SEM, for n > 3 per dosage point. (C, D) Flow cytometry analysis to compare the expression of cell
surface apoptotic marker annexin v between control cells and DSTYK/KO cells after a 48 h OXA treatment, 4 µM in (C); 2 µM in (D). Red curves represent control
LS411N-TbRII cells or LS513 cells. Blue curves represent DSTYK/KO LS411N-TbRII cells or LS513 cells. ‘-’ means without OXA treatment. ‘+’ means with OXA
treatment for 48h. (E, F) Quantiﬁcation of the ﬂow cytometry analyses in (C, D), respectively. (G, H) Clonogenic assays and the corresponding quantiﬁcation results.
All experiments were repeated at least three times and similar results were observed. *P < 0.05; **P < 0.01.

orthotopic tumor mouse models. In the xenograft model, 2 × 105
LS411N-TbRII control cells or 2 × 105 DSTYK/KO LS411N-Tb RII
cells were subcutaneously implanted into the ﬂanks of 7- to 8-weekold SCID mice. OXA (10–20 mg/kg) was applied to mice 2 times/
week intraperitoneally for 3–4 weeks. After treatments, the size,
weight, and growth of tumors from LS411N-TbRII DSTYK/KO
cells had regressed signiﬁcantly more than those tumors from
LS411N-TbRII control cells (Figures 6A–C), which suggests that
DSTYK inhibits chemotherapeutic drug-induced tumor cell death.
These results indicate that DSTYK can attenuate the
chemosensitivity of tumor cells by inhibiting chemotherapeutic

Frontiers in Pharmacology | www.frontiersin.org

drug-induced apoptosis of tumor cells. Moreover, analyses of IHC
revealed that signiﬁcantly reduced numbers of Ki-67–positive and
increased cleaved caspase-3–positive tumor epithelial cells were
found in cecal tumors derived from LS411N-TbRII DSTYK/KO
cells after OXA treatment when compared to that of control cells
(Figure 6D). Furthermore, we employed the orthotopic metastatic
mouse model in which cells were injected directly into the cecal wall
of the SCID mice. DSTYK/KO cells resulted in a signiﬁcant increase
of survival rates and much fewer metastatic lesions in livers and the
overall liver tumor burden from LS411N-TbRII DSTYK/KO
cells when compared to those of control cells (Figures 6E, F and
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Table 1). Similar results were obtained from experiments performed
with LS513 control cells and LS513 DSTYK/KO cells as shown in
Supplementary Figure 3 and Supplemental Table 2. Collectively,
all these results indicate that DSTYK can attenuate the
chemosensitivity and promote metastasis of tumor cells by
inhibiting chemotherapeutic drug-induced apoptosis and
facilitate EMT.

the expression of DSTYK not only is correlated with EMT
markers but also related to the survival of CRC patients.
Furthermore, we identify DSTYK as a novel effector in TGF-binduced EMT in CRC cells using both in vitro and in vivo
systems. DSTYK is required for TGF-b-induced EMT and
DSTYK knockout via Crispr/Cas9 shifts TGF-b-induced EMT
to apoptosis. Further, we also characterize the role of DSTYK in
chemoresistance during chemotherapeutic drug treatment:
DSTYK promotes chemoresistance by inhibiting apoptosis.
We found that DSTYK is upregulated during TGF-b-induced
EMT in a gene microarray analysis. Previously, the exact biological
role of DSTYK remained unresolved. DSTYK was once identiﬁed
to be a major determinant of human urinary tract development,
downstream of FGF signaling (Sanna-Cherchi et al., 2013). Other
studies showed that DSTYK knockdown in zebraﬁsh caused severe
developmental defects, suggesting its important role during
embryonic development (Sanna-Cherchi et al., 2013). DSTYK
homozygous knockout mice exhibited impaired learning and

DISCUSSION
Accumulated evidence indicates that the EMT is associated with
features of advanced cancer progression, including metastasis
and chemotherapeutic resistance (Polyak and Weinberg, 2009;
Wendt et al., 2009; Mao et al., 2017). However, the mechanism of
TGF-b-induced EMT in tumor metastasis and chemotherapeutic
resistance remains unclear in CRC. In this study, we describe the
functions of DSTYK in human CRC cells and demonstrate that

A

B

C

D
E

F

G

FIGURE 6 | DSTYK knockout facilitates tumor regression after OXA treatment. For each mouse, control LS411N-TbRII cells were implanted into the right ﬂank and
DSTYK/KO LS411N-TbRII cells were implanted into the left ﬂank (n=20 per group). After around 3 weeks, mice carrying two tumors of similar size (tumor diameter is
around 50 mm as measured with a caliper) started receiving OXA twice weekly. A tumor volume of 1300 mm3 was deﬁned as the survival endpoint. Tumors were
excised (A) and tumors’ weights were evaluated as a box-and-whisker plot (B). Data is presented as mean ± SD. (C) The growth curves of control tumors and
DSTYK/KO tumors with and without OXA treatment, n=10 per group. (D) The levels of Ki-67 and cleaved caspase-3 in tumors tissues from LS411N-TbRII control
cells and LS411N-TbRII DSTYK/KO cells detected by immunohistochemical analyses. Scale bar, 50 µm. (E) Representative images of liver metastasis (arrows).
(F) Kaplan-Meier curve assessing the survival of SCID mice injected with LS411N-TbRII control cells or LS411N-TbRII DSTYK/KO cells in cecum wall (n=10/group, 3x).
*P < 0.05; **P < 0.01. (G) The proposed model for the mechanism underlying the expression and function of DSTYK in TGF-b-induced EMT and chemoresistance.

TABLE 1 | DSTYK regulates the metastasis of LS411N-TbRII cells implanted in the cecum of SCID mice.
Treatment group
Control
DSTYK/KO

Tumor volume(mm3, mean)

Cecum tumor weight (g, mean)

Survival

Liver metastasis

1833
1637

2.5
2.6

2/10
10/10

10/10
0/10

Frontiers in Pharmacology | www.frontiersin.org

9

September 2020 | Volume 11 | Article 1250

Zhang et al.

DSTYK in EMT and Chemoresistance

the expression of DSTYK in colorectal cancer cells. Without
DSTYK, TGF-b induces cell apoptosis instead of EMT.
Furthermore, chemotherapy is the standard ﬁrst-line treatment
option for CRC patients with metastatic unresectable disease
(Van Cutsem et al., 2016; Munker et al., 2018). OXA has been
considered as the ﬁrst‐line chemotherapeutic drug in colorectal
cancer treatment (Hsu et al., 2018). Most therapeutic efforts now
are focused on validating a novel potential biomarker of tumor
progression or response to drug treatment. Our in vivo data,
from both xenograft and orthotopic mouse models, conﬁrm that
DSTYK plays an important role in promoting both tumor
metastasis and resistance to OXA therapy. Our ﬁndings will
aid to the development of therapeutic strategies to overcome
CRC metastasis and resistance to chemotherapy. The mechanism
we describe here (Figure 6G) will enable more efﬁcient
therapeutic strategies to improve patient outcomes.
In summary, DSTYK is highly expressed in metastatic CRC; it
confers enhanced invasive ability and chemoresistance to CRC
cells. DSTYK may be an excellent biomarker for evaluating the
signiﬁcance of CRC metastasis clinically. Targeting DSTYK may
provide novel therapeutic approaches for considerably extending
the survival rate of CRC patients.

memory capacity compared with that of heterozygous mice (Li
et al., 2014). To determine whether DSTYK plays a role in
tumorigenesis of colorectal cancer we characterized DSTYK
expression in the Gene Expression Omnibus (GEO) and TCGA
databases and found that DSTYK is strongly expressed in the
cytoplasm of most malignant cells and that the high expression of
DSTYK in human colon cancer specimens is associated with
tumor progression and/or poor prognosis (Ponten et al., 2011).
Although the limited databases concluded that DSTYK is not a
prognostic marker in colorectal cancer, the low expression of
DSTYK indeed prolongs patients’ life span. Consistent with these
ﬁndings, we report here that DSTYK protein levels are much
higher in human CRC metastatic tumors, including those in lung
and liver, than in primary clinical tumor samples of CRC patients.
Currently, a lot of factors, inducers and proteins have been
identiﬁed to be involved in the EMT contributing to metastasis
in CRC (Shioiri et al., 2006; Saito et al., 2008; Yan et al., 2015;
Weng et al., 2016). In this study we identify a novel element,
DSTYK, which plays an important role in TGF-b-induced EMT.
Statistically, in our analyses DSTYK is signiﬁcantly correlated with
N-cadherin, vimentin, and TGF-b, but inversely correlated with Ecadherin. We hypothesized that DSTYK, as a novel effector, plays
an important role in CRC metastasis and chemoresistance.
Therefore, we employed both an in vitro cell model and two in
vivo mouse models to conﬁrm our hypothesis.
Previous reports mostly focused on EMT induced by TGF-b
through the canonical Smads signaling pathway in microsatellite
stable (MSS) colorectal cancer cell lines, such as HT29 and SW480
(Ahmed et al., 2013; Mouradov et al., 2014). We also observed the
upregulation of DSTYK during TGF-b-induced EMT in these cells.
However, to generalize our hypothesis, we explored additional cells
lines LS411N (microsatellite instable, MSI) and LS513 (MSS). The
LS411N cells express a mutated TbRII and are completely
unresponsive to TGF-b induction and are impaired in EMT. In
contrast, LS513 cells are more sensitive to TGF-b induction and
show strong TGF-b-induced EMT. To render LS411N TGF-b
competent, we stably overexpressed wild-type TbRII in LS411N
cells and established the LS411N-TbRII cell line. As expected, TGFb not only signiﬁcantly decreases the epithelial cell marker, Ecadherin, but also increases the mesenchymal markers, N-cadherin
and vimentin, in both LS411N-TbRII and LS513 cells. These three
EMT makers are commonly used to afﬁrm and characterize the
EMT process (Lee et al., 2006). In addition, we ﬁnd that TGF-b
induced the expression of DSTYK transcriptionally. Therefore, our
ﬁndings provide a novel mechanism for the TGF-b induction of
EMT in CRC cells (Pino et al., 2010; Rocha et al., 2018; Yang et al.,
2019), and also establish two new CRC cell lines to study TGFbinduced EMT and metastasis.
Liu et al. reported that TGF-b activated the PI3K/AKT
pathway in HCT116 WT-TbRII cells to promote liver
metastasis, and a PI3K inhibitor attenuated this effect (Liu
et al., 2011). Here we ﬁnd that after knockout of DSTYK using
the Crispr/Cas9 technique, TGF-b treatment failed to induce
EMT in CRC cells. Interestingly, we see signiﬁcant induction of
apoptosis instead of EMT in the treated cells when compared to
control cells (Figure 4). TGF-b–induced EMT is dependent on
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CONCLUSION
These studies establish the role of DSTYK in both TGF-binduced EMT and the chemoresistance in CRC cells. Using
engineered cells with modulated DSTYK expression and using
an orthotopic mouse model, DSTYK’s mechanism of action and
translational signiﬁcance are elucidated to provide insight into
DSTYK’s potential as a therapeutic target for CRC therapy.
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